NewsLANCET (LONDON, ENGLAND)Sunday, April 19, 2026 · April 19, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
WHY IT MATTERS
Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improves progression-free survival and overall survival compared with weekly paclitaxel, with or without bevaciz...
Related conditions
Related news
Int J Circumpolar Health · -249 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -219 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -219 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
Mol Ther Nucleic Acids · -51 days ago
The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena
Published in Mol Ther Nucleic Acids. Giangrande PH et al.…